Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin’s lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions to rituximab is high. Reactions to monoclonal antibodies, including rituximab, vary widely in type and severity, but may include mild pruritis and rash to more severe complications such as Stevens-Johnson syndrome and anaphylactic reactions.
Objective: To assess the incidence of infusion-associated reactions in our MS patients receiving rituximab infusions and compare it to previous trials investigating rituximab for treating MS.
Methods: From 1 to 30 November 2009, we retrospectively reviewed medical charts from Partners Multiple Sclerosis Centre, Brookline, MA, USA, of patients being treated with rituximab for MS between 20 November 2007 and 24 November 2009 for evidence of infusion-associated reactions and further classified reactions on a grading scale.
Results: During the period studied, 70 patients were infused with rituximab. Infusion-associated events occurred in 25.7% of our patients. Reactions were mild to moderate and most commonly occurred during the first infusion. Most patients were able to complete the infusion after appropriate treatment of the reaction was administered, and most patients went on to receive subsequent doses without any further reactions.
Conclusions: The occurrence of infusion-associated reactions to rituximab in patients with MS is fairly common. However, premedication that includes corticosteroids may reduce the incidence of reactions dramatically. Should they occur, proper treatment of reactions with histamine H1 or H2 receptor antagonists and infusion rate reduction is an effective management strategy in this situation.
- Rituxan® (rituximab) [package insert]. San Francisco (CA): Biogen Idec Inc. and Genentech, 2009
- Sailler, L (2008) Rituximab off-label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol 34: pp. 103-10 CrossRef
- Compston, A, Coles, A (2008) Multiple sclerosis. Lancet 372: pp. 1502-17 CrossRef
- Lassmann, H (2008) Models of multiple sclerosis: new insights into pathophysiology and repair. Curr Opin Neurol 21: pp. 242-7 CrossRef
- Interferon beta-1b is effective in relapsing remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: pp. 655-61 CrossRef
- Johnson, KP, Brooks, BR, Cohen, JA (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: pp. 1268-76 CrossRef
- Jacobs, LD, Cookfair, DL, Rudick, RA (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: pp. 285-94 CrossRef
- Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: pp. 1498-504 CrossRef
- Polman, CH, O’Connor, PW, Havrdova, E (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: pp. 899-910 CrossRef
- Rudick, RA, Stuart, WH, Calabresi, PA (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: pp. 911-23 CrossRef
- Franciotta, D, Salvetti, M, Lolli, F (2008) B cells in multiple sclerosis. Lancet Neurol 7: pp. 852-8 CrossRef
- Dalakas, MC (2006) B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112: pp. 57-70 CrossRef
- Hauser, SL, Waubant, E, Arnold, DL (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: pp. 676-88 CrossRef
- Common terminology criteria for adverse events v3.0 (CTCAE): online instructions and guidelines. Bethesda (MD): National Cancer Institute, August 9, 2006 [online]. Available from URL: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf [Accessed 2010 Jan 6]
- Gaston, RS, Zeierhoi, MH, Patterson, T (1991) OKT3 first dose reaction: association with T cells subset and cytokines release. Kidney Int 39: pp. 141-7 CrossRef
- Albrecht, H, Radosevich, JA, Babich, M (2009) Fundamentals of antibody-related therapy and diagnostics. Drugs Today (Barc) 45: pp. 199-211 CrossRef
- Calogiuri, G, Ventura, MT, Mason, L (2008) Hypersensitivity reactions to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 14: pp. 2883-91 CrossRef
- Cohen, SB, Emery, P, Greenwald, MW (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 54: pp. 2793-806 CrossRef
- Merrill, JT, Neuwelt, CM, Wallace, DJ (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum 62: pp. 222-33 CrossRef
- McLaughlin, P, Hagemeister, FB, Grill-Lopez, AJ (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26: pp. 79-87
- Hawker, K, O’Connor, P, Freedman, MS (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multi-center trial. Ann Neurol 66: pp. 460-71 CrossRef
- Bar-Or, A, Calabresi, PAJ, Arnold, D (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: pp. 395-400 CrossRef
- Schwartzberg, LS, Stepanski, EJ, Fortner, BV (2008) Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 16: pp. 393-8 CrossRef
- Lenz, HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12: pp. 601-9 CrossRef
- Lenz, HJ (2006) Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20: pp. 5-13
- Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis
Volume 34, Issue 2 , pp 117-123
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors